The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product
Here's a roundup of top developments in the biotech space over the last 24 hours:
Biofrontera Q1 EPS $0.32 Up From $(0.44) YoY, Sales $9.75M Miss $9.90M Estimate; Reaffirms Guidance
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.32 per share. This is a 172.73 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $9.75
Peering Into Biofrontera Inc. – Common Stock’s Recent Short Interest
Biofrontera Inc. - Common Stock's (NASDAQ:BFRI) short percent of float has risen 6.56% since its last report. The company recently reported that it has 821.90 thousand shares sold short, which is 15.93% of all regular shares that are available for trading.
Why Biofrontera Stock Is Surging Today
Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million.
Biofrontera Q4 Net Loss $14.5M vs Loss $200K In Same Qtr. Last Year, Adj. EBITDA Loss $3.2M vs Loss $3K Year Over Year, Sales $9.20M Miss $9.24M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly sales of $9.20 million which missed the analyst consensus estimate of $9.24 million by 0.43 percent. This is a 6.98 percent increase over sales of $8.60 million the same
16 Stocks Moving in Friday’s Pre-Market Session
Gainers
Biofrontera Inc. (NASDAQ: BFRI) rose 34.5% to $5.44 in pre-market trading.